Key Points
- COO Xiaobin Wu sold 6,009 shares on Nov. 13 at an average price of $380.54 for $2.29M and also sold 10,000 shares on Nov. 12 at $356.02 for $3.56M, totaling about $5.85M in insider sales over two days.
- BeOne shares traded at $365.82 midday (near a 1‑year high of $381.50), with a market cap of $40.12B and a very high trailing PE of 717.29.
- Institutional investors own about 48.55% of the stock, and analysts carry a consensus rating of "Moderate Buy" with a consensus target of $357.33 amid several recent price‑target upgrades up to $405.00.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 996 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $349.17, for a total transaction of $347,773.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, October 8th, Chan Henry Lee sold 10,671 shares of BeOne Medicines stock. The shares were sold at an average price of $350.40, for a total value of $3,739,118.40.
- On Wednesday, September 10th, Chan Henry Lee sold 10,006 shares of BeOne Medicines stock. The shares were sold at an average price of $325.53, for a total value of $3,257,253.18.
BeOne Medicines Price Performance
Shares of ONC traded down $2.54 during mid-day trading on Friday, reaching $365.82. The stock had a trading volume of 230,040 shares, compared to its average volume of 257,949. The business has a fifty day moving average of $329.90 and a 200 day moving average of $291.46. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a market cap of $40.12 billion, a price-to-earnings ratio of 717.29 and a beta of 0.31. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $381.50.
Wall Street Analyst Weigh In
Several research firms recently weighed in on ONC. Guggenheim raised their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $345.00 to $385.00 and gave the company an "overweight" rating in a research report on Wednesday, October 8th. Royal Bank Of Canada lifted their target price on BeOne Medicines from $374.00 to $395.00 and gave the stock an "outperform" rating in a report on Friday, November 7th. Wall Street Zen raised BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BeOne Medicines currently has a consensus rating of "Moderate Buy" and an average target price of $357.33.
Get Our Latest Stock Analysis on ONC
Institutional Investors Weigh In On BeOne Medicines
Several hedge funds and other institutional investors have recently modified their holdings of ONC. Creative Planning boosted its stake in shares of BeOne Medicines by 49.7% during the third quarter. Creative Planning now owns 8,951 shares of the company's stock valued at $3,050,000 after purchasing an additional 2,970 shares during the period. Lazard Asset Management LLC raised its holdings in shares of BeOne Medicines by 74.7% in the third quarter. Lazard Asset Management LLC now owns 41,380 shares of the company's stock valued at $14,098,000 after acquiring an additional 17,688 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of BeOne Medicines by 4.2% in the 3rd quarter. Raymond James Financial Inc. now owns 17,196 shares of the company's stock worth $5,859,000 after purchasing an additional 693 shares during the period. Qtron Investments LLC boosted its stake in shares of BeOne Medicines by 12.4% during the third quarter. Qtron Investments LLC now owns 3,742 shares of the company's stock valued at $1,275,000 after purchasing an additional 412 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of BeOne Medicines in the 3rd quarter valued at $1,052,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
